The main purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in adults with severe postpartum depression (PPD). SAGE-217 is is an investigational drug, which means that it is not yet approved to treat PPD. Participation in the study will last up to 76 days and includes a 14 day treatment period where SAGE-217 is taken by oral pill daily. Visits will take approximately 1 to 3 hours.

The objective of this study is to obtain viable mesenchymal stem cells (MSCs) from umbilical cords in uncomplicated planned cesarean deliveries. Potential donors will be screened prior to donation of umbilical cords to confirm no infectious disease, viruses and/or diseases. The overall goal is to obtain MSCs from healthy donors for eventual transfusion into patients for potential treatment of diseases, such as chronic pancreatitis, systemic sclerosis, type 1 diabetes, COVID 19, acute respiratory distress syndrome (ARDS), and other diseases in studies approved by the IRB. We also want to store the cells as repository for other potential therapy.

This study is to develop a rapid molecular diagnostic test for the detection of Group B Strep (GBS). This study will collect specimens from pregnant women for the development of a prototype assay.

We are comparing standard in-office postpartum blood pressure monitoring to at-home monitoring for patient diagnosed with hypertensive disorders of pregnancy.

The primary purpose of this study is to compare extended-release buprenorphine (CAM2038) to buprenorphine placed under the tongue (sublingual) in pregnant women with opioid use disorder to see if CAM2038 is as effective as sublingual buprenorphine. We are looking to recruit pregnant women who are between 18-41 years old; are between 6-30 weeks pregnant and are not planning to terminate the pregnancy; have opioid use disorder, and are enrolled or are planning to enroll in outpatient buprenorphine treatment at The Medical University of South Carolina. Participation in the study would last between 13 and 21 months total with up to between about 63-102 total visits, including weekly medication check visits and research visits.

Staff at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience.

This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder, as well as a text message based mental health and substance use screening and treatment program for pregnant and postpartum women, called Listening to Women (LTW). Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years of any race who misuse opioids or have opioid use disorder, obstetric providers who treat pregnant women with opioid misuse and opioid use disorder and women who self-identify as Black that has been pregnant or postpartum in the past 2 years and struggled with a substance use disorder or mental health disorder during this time OR did NOT struggle with a substance use disorder or mental health disorder during this time to participate in this study.

We propose to play the song "Weightless" during epidural placement on an iPhone set to medium volume. The song (all 6 continual parts) is 43 minutes long and will be started just before epidural placement and stopped just after end of procedure. The control group will be expectant mothers who do not have "Weightless" playing during their epidural placement. The goal is to determine if playing "the most relaxing song in the world" helps to reduce laboring parturients anxiety and improve their overall satisfaction with the experience.

This study will compare 0.1mg and 0.05mg of spinal morphine for postoperative pain after scheduled, elective Cesarean delivery. All patients will receive a spinal anesthetic (single injection in the lower back to numb patients from the waist down) for operative anesthesia and will be
randomized into one of two groups: (group 1) 0.1mg spinal morphine and (group 2) 0.05mg spinal morphine. This will be a randomized, single blinded study.

This study will evaluate a remote patient monitoring solution for low-risk pregnancies to assess whether or not it produces equivalent care with regards to clinical outcomes and patient satisfaction at a lower cost to the healthcare system and its participants. Furthermore, we will measure the ability of participants to collect and record the necessary data.